JAKs, stats, and CK2?

Abstract

Activating mutations in JAK2, a tyrosine kinase that serves as a critical signaling protein for multiple cytokines, are associated with BCR-ABL1-negative myeloproliferative neoplasms. In this issue of Blood, Zheng and colleagues report that the constitutively activated kinase CK2 binds to JAK2 and is required for JAK-Stat signaling, suggesting that CK2 inhibitors may provide a second, complimentary therapeutic for diseases with elevated JAK2 signaling, such as myeloproliferative neoplasms.